Dear Chief Editor of Jurnal Pharmascience,

We have sent the manuscript of our research entitled "Molecular Basis for the Enhanced CDK2 Inhibition by Artesunate: Superior Binding Affinity to the ATP-Catalytic Site".

This manuscript contains some new findings in the field of drug design and discovery, including the discovery of artesunate as CDK-2 inhibitor as well as found it's mechanism of action as ATP-competitive inhibitor. We also compare artesunate affinity with several known CDK2-inhibitor and find certain amino acid residues with the important role in artesunate affinity. The results are promising and have the potential to be developed in future research.

We highly appreciated if you could give us positive feedback within 2-3 weeks. We also inform you that this our original research that hasn't been published elsewhere. Thank you for your kind attention and we look forward to your good news soon.

Best regards,

Dr. apt. Mohammad Rizki Fadhil Pratama, M.Si.

Department of Pharmacy, Universitas Muhammadiyah Palangkaraya, Indonesia

ORCID: https://orcid.org/0000-0002-0727-4392